Siegfried lifts profitability and expands U.S. footprint amid cautious 2026 outlook

An announcement from Siegfried Holding AG ( (CH:SFZN) ) is now available.

Siegfried reported 2025 net sales of CHF 1.33 billion, up 4.3% in local currencies, with particularly strong contributions from its Drug Substances and Drug Products clusters and record core profitability metrics. The company combined disciplined cost and portfolio management with stepped‑up capital expenditure to expand manufacturing capacity, while maintaining a solid balance sheet and modest leverage.

Execution of the EVOLVE+ strategy drove a sharp increase in customer requests and project wins, underpinned by targeted technology upgrades in ophthalmic, spray‑drying and fill‑finish capabilities and the ramp‑up of new plants in Minden and Schlieren. A strategic acquisition of small‑molecule drug substance assets in the U.S. and Australia, along with a streamlined operations leadership structure, is set to strengthen Siegfried’s position in the world’s largest pharma market, even as 2026 guidance reflects cautious assumptions for Drug Substances and confirms resilient margins and above‑market mid‑term growth ambitions.

The most recent analyst rating on (CH:SFZN) stock is a Hold with a CHF108.00 price target. To see the full list of analyst forecasts on Siegfried Holding AG stock, see the CH:SFZN Stock Forecast page.

More about Siegfried Holding AG

Siegfried Holding AG is a global life sciences company and contract development and manufacturing organization (CDMO) with sites in Switzerland, Germany, Spain, France, Malta, the U.S. and China. The group focuses on producing small‑molecule drug substances and drug products for both large pharmaceutical companies and small‑ to mid‑cap innovators, with a highly diversified commercial‑phase portfolio.

Average Trading Volume: 121,003

Technical Sentiment Signal: Strong Buy

Current Market Cap: CHF4.06B

See more data about SFZN stock on TipRanks’ Stock Analysis page.